Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens

NCT07694648 · tracked via the Priya Life Science China tracker

Sponsor

Huashan Hospital

Phase

Observational

Started

2025-09-01

Last updated

2026-07-10

Condition(s) studied

Respiratory Tract Infections (RTI)Respiratory Syndrome, Acute, SevereAcute Respiratory Infections (ARIs)

Investigational drug(s) / intervention(s)

Tiered pathogen testing and multi-omics analysis

Tiered pathogen testing and multi-omics analysis: Participants will undergo clinically indicated tiered testing, including SARS-CoV-2 nucleic acid testing, influenza A/B antigen or nucleic acid testing, routine blood testing, targeted sequencing or multiplex PCR, metagenomic next-generation sequencing, respiratory pathogen antibody testing, cytokine testing, and exploratory transcriptomics, metabolomics, proteomics, single-cell, microbiome, and related analyses using collected or clinically remaining samples.

Study summary

This nationwide, multicenter observational study will establish and improve a hospital-based clinical surveillance and early warning system for respiratory syndrome pathogens. Clinical data and biospecimens generated during routine care will be collected from participating medical institutions every two weeks to monitor pathogen trends, support risk assessment, and provide evidence for prevention and control measures.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients with respiratory syndrome: Eligible patients are those diagnosed with respiratory syndrome based on the predefined data dictionary and the following ICD-10 (International Statistical Classification of Diseases, 10th Revision) diagnosis codes: R05, R50, J00, J01, J02, J03, J04, J06, J07, J08, J09, J10, J11, J12, J13, J14, J15, J16, J17, J18, J20, J21, J98.414, and J98.802. * Patients with respiratory syndrome: Eligible patients are identified using the following search criteria. Patients meeting any one of the following criteria should be included: 1. Medical history (History of Present Illness): Positive test result for a respiratory syndrome-related pathogen. 2. Laboratory testing: Positive test result for a respiratory syndrome-related pathogen. 3. Medication: Receipt of any of the following antiviral agents: Nirmatrelvir/Ritonavir Leritrelvir Xiannuotewei/Ritonavir Molnupiravir Azvudine Deuremidevir 4. Diagnosis: Diagnosis containing the term "respiratory tract infection." Exclusion Criteria: * Participants who may compromise the study results: Patients who are unable to provide a specimen or whose specimen volume is insufficient for laboratory testing. * Participants who are unable to comply with study procedures.

Primary outcome measure(s)

Detection rate and pathogen spectrum of respiratory syndrome pathogens among enrolled participants — 3 years
Immune response and antibody levels after respiratory syndrome-related infection or vaccination — 3 years

Trial sites (31)

Facility	City	Region	Status
Beijing You'an Hospital, Capital Medical University	Beijing	Beijing Municipality	Recruiting
The Fifth Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong	Recruiting
The Fifth Affiliated Hospital of Sun Yat-sen University	Zhuhai	Guangdong	Recruiting
The 980th Hospital of the People's Liberation Army Joint Logistics Support Force	Shijiazhuang	Hebei	Recruiting
Heilongjiang Provincial Hospital	Harbin	Heilongjiang	Recruiting
Jiamusi Central Hospital	Jiamusi	Heilongjiang	Recruiting
Shangqiu Municipal Hospital	Shangqiu	Henan	Recruiting
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan	Recruiting
Yichang Third People's Hospital	Yichang	Hubei	Recruiting
Hunan University of Medicine General Hospital	Huaihua	Hunan	Recruiting
The Third Hospital of Baotou (Baotou City Hospital for Infectious Diseases)	Baotou	Inner Mongolia	Recruiting
Nanjing Hospital of Chinese Medicine	Nanjing	Jiangsu	Recruiting
The Third People's Hospital of Nantong (Nantong Hospital of Infectious Diseases)	Nantong	Jiangsu	Recruiting
Wuxi Fifth People's Hospital	Wuxi	Jiangsu	Recruiting
Jiujiang No.1 People's Hospital	Jiujiang	Jiangxi	Recruiting
Shenyang Sixth People's Hospital	Shenyang	Liaoning	Recruiting
Affiliated Hospital of Yan'an University	Yan’an	Shaanxi	Recruiting
Zaozhuang Municipal Hospital	Zaozhuang	Shandong	Recruiting
Huashan Hospital Fudan University	Shanghai	Shanghai Municipality	Recruiting
Shanghai East Hospital	Shanghai	Shanghai Municipality	Recruiting
Jinyang Community Health Service Center of Pudong New Area, Shanghai	Shanghai	Shanghai Municipality	Recruiting
Shanghai Sixth People's Hospital	Shanghai	Shanghai Municipality	Recruiting
Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center	Shanghai	Shanghai Municipality	Recruiting
First Hospital of Shanxi Medical University	Taiyuan	Shanxi	Recruiting
Children's Hospital of Shanxi Province	Taiyuan	Shanxi	Recruiting
Characteristic Medical Center of Chinese People's Armed Police Force	Tianjin	Tianjin Municipality	Recruiting
Altay Prefecture People's Hospital, Xinjiang	Altay	Xinjiang	Recruiting
Changji Hui Autonomous Prefecture People's Hospital	Changji	Xinjiang	Recruiting
The First Affiliated Hospital of Xinjiang Medical University	Ürümqi	Xinjiang	Recruiting
Hekou Yao Autonomous County People's Hospital	Hekou	Yunnan	Recruiting
The First People's Hospital of Yunnan Province	Kunming	Yunnan	Recruiting

More Huashan Hospital trials in China

Real World Study of End-stage Liver Disease in China Recruiting

Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial Recruiting

Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma Starting soon

Efficacy and Safety of Spinal Cord Stimulation in Patients With Spinal Cord Stimulation Recruiting

RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China Starting soon

Other trials for the same condition

RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China Starting soon

The Influence of Explainability and Integrability of AI-CDSS on Usage Behavior Among Primary Care Physicians Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07694648 on ClinicalTrials.gov ↗ ← All trials in China